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The blood supply to tumors may be provided through a number of mechanisms, including intussusceptive angiogenesis, recruitment of endothelial progenitor cells, vessel co-option and vasculogenic mimicry. Hemangioblasts are known to generate both hematopoietic and endothelial lineages in early embryonic life. Currently, several studies demonstrate the presence of cells containing clonotypic, cancer-causing mutations within microvessel endothelial cells in certain cancers. 2, 3 These findings suggest that certain leukemias originate from bone marrow-derived hemangioblasts or become hemangioblasts that can give rise to both malignant blood cells and endothelial cells. Infant leukemia associated with t(4;11) is particularly aggressive and difficult to cure. Microarray studies showing that t(4;11) leukemia cells have a hemangioblastic phenotype 4, 5 suggest that therapy targeting angiogenesis might be a fruitful approach to treating this deadly disease. To determine the potential role of antiangiogenesis therapy in infant leukemia, we investigated whether infant leukemia cells behave like hemangioblasts and produce their own blood vessels as they invade into tissues.
For this purpose, we analyzed the expression of angiogenic cytokines and receptors in mRNA and protein levels in our t(4;11) acute lymphoblastic leukemia cell lines SEM-K2 and RS4;11, and acute myeloid leukemia (AML) cell line MV4-11 and in primary leukemia cells of two pateints with t(4;11) from two patients. We used quantitative real-time reverse transcription PCR to measure the expression levels of endothelial celland hemangioblast-related receptors. To standardize the mRNA content, we used glyceraldehyde-3-phosphate dehydrogenase as the endogenous control and human umbilical vascular endothelial cells (HUVECs) as the reference sample. The amount of target relative to reference sample was calculated as 2 ÀDDCt , as described earlier. 6 As shown in Table 1 , we found that t(4;11) leukemia cells expressed mRNA for EPOR at high levels, but expressed that for vWF, Tie-2 and KDR at low levels or beyond detection. MV4-11 expressed EPOR and VE-cadherin at higher levels, whereas RS4;11 expressed CD34 and SEM-K2 vWF at higher levels.
Flow cytometry was used to investigate the expression of angiogenic receptors in t(4;11) leukemia cell lines and primary cells. It showed that t(4;11) infant leukemia cells express angiogenic receptors in a variety of patterns. The human acute monocytic leukemia cell line, MV4-11, strongly expressed the endothelial cell-surface antigens CD31, CD141, Tie-2, KDR and PDGFRa at a similar level to HUVEC. Only sub-populations of cells from the other two acute lymphoblastic leukemia cell lines (RS4;11 and SEM-K2) expressed CD31, Tie-2, CD146, KDR and Flt-1. Primary cells from a patient with recurrent t(4;11) expressed a higher level of CD34, but very low levels of Tie-2, CD31, CD141, KDR and Flk-1. Two frozen primary leukemia samples with t(4;11) from Children's Oncology Group expressed CD34, Tie-2 and KDR at higher levels. However, they expressed Flt1 at levels similar to MV4-11 cells (see Supplementary Table 2 and Supplementary Figure 1 in  supplementary) .
For a more complete view of the expression of angiogenic proteins, we used protein array to evaluate angiogenic protein expression profiles of cell lines containing t(4;11) in comparison with human endothelial cell line HUVEC and human CD34 þ bone marrow cells. We found that MV4-11 expressed most of the angiogenic cytokines in a pattern that was similar to that in HUVEC cells. SEM and RS4;11 expressed the angiogenic cytokines epidermal growth factor, insulin-like growth factor-1, interleukin-6, interleukin-8, RANTES, transforming growth factor-b1, tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2, at levels similar to those in HUVEC cells and human CD34 þ cells from the bone marrow. CD34 þ cells expressed the highest levels of these cytokines. In primary samples, one of the two leukemia samples with t(4;11) expressed angiogenin, epidermal growth factor, GRO and RANTES at higher levels (see Supplementary Table 3 in  supplement) . Once again, the expression of angiogenic proteins was variable.
Ang 1 and vascular endothelial growth factor (VEGF) were reported to be expressed in different kinds of leukemia cells. They are important for vascular network formation and remodeling. We also used enzyme-linked immunosorbent assay to detect the expression of these two proteins in the cell culture supernatant of our leukemia cells with t(4;11). We found that SEM-K2 expressed Ang 1 at a high level (2939.6 pg/ml), compared with HUVEC (283.7 pg/ml). In the case of VEGF expression, MV4-11 expressed at a high level (41500 pg/ml), SEM-K2 at a level of 443 pg/ml and RS4;11 and HUVEC at low levels (o30 pg/ml). This result was consistent with 
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Ghannadan's 7 report that AML blasts produce and secrete VEGF protein. Overall, these observations support the idea that infant leukemia cells can secrete angiogenic factors that may interact with functional receptors to recruit blood vessels or resulting in autocrine loops that promote leukemia progression. These data do not support the idea that infant leukemia cells produce angiogenic proteins or receptors in any consistent or predictable pattern.
In vitro angiogenesis assay with Matrigel is widely used as a standard method to confirm the endothelial activity. An earlier study demonstrated that bone marrow cells from patients with chronic myelogenous leukemia produced vascular tubes in Matrigel. 2 We tested whether t(4;11) leukemia cells formed vascular tubes in a standard in vitro angiogenesis assay. Neither t(4;11) leukemia cell lines nor primary leukemia cells from t(4;11) infant leukemia patients (n ¼ 3) produced vascular tubes in Matrigel (see Supplementary Figure 2 in supplement) . This result is consistent with the study by Riccioni, 8 which showed that Tie-2-positive AML blasts increased expression of many of the endothelial markers, such as Tie-2, VEGF-R1 and -R2, CD144 and CD146, after being cultured under endothelial cell culture conditions. But they failed to form tube-like structures in Matrigel plate.
When leukemia develops in the human bone marrow, increased microvascular density levels have been observed in a number of types of hematologic malignancies, suggesting a state of increased angiogenesis. We wondered whether t(4;11) leukemia cells incorporated into developing blood vessels in the bone marrow or in tumors in NOD/SCID mice. We injected 0.7-3 Â 10 7 leukemia cells into the sublethally (350 cGy) irradiated NOD/SCID mice through the tail vein. We found that levels of human tumor infiltration of the murine bone marrow varied depending upon the cell line used, with up to 7% of the bone marrow mononuclear cells consisting of human leukemic blasts with MV(4;11), 99% with RS4-11 and intermediate levels with SEM. Levels of infiltration by human cells were quantified by flow cytometry (Figure 1a) and confirmed by immunohistochemistry. We stained these samples with anti-human von Willibrand factor (Figure 1b 3-4) , CD31 and CD34 (figures not shown), and with the murine pan-endothelial marker, MECA-32 (Figure 1b 7-8) , to determine whether the vessels in these areas were derived from the human leukemia cells or from mouse endothelial progenitors. Contrary to our hypothesis, these areas lacked cells that expressed human vascular proteins. In contrast, vascular endothelium in these tumor-infiltrated areas expressed the murine pan-endothelial antigen, MECA-32, confirming that they were generated by the murine host. Vessels within the tumors also expressed MECA-32 in the eyes (b8) and muscle (data not shown). As these particular tissues (bone marrow and eye) are full of capillaries, it was possible that the human leukemia cells did not need to recruit blood vessels to receive nutrients, but rather simply grew Letters to the Editor between the individual capillaries of these capillary beds. We therefore sought to test the ability of t(4;11) leukemia cells to recruit or contribute to the walls of blood vessels in models that promoted new vascular growth.
When we mixed t(4;11) leukemia cells with Matrigel and injected the mixture subcutaneously into NOD/SCID mice, tumor cells initially grew along the internal edge of Matrigel plug when assessed 10 days to 1 month after injection (data not shown). One to two months after injection, the leukemia cells developed large tumors in the Matrigel plug. The tumor cells expressed human CD31. Individual tumor cells were confirmed to come from human leukemia cells by the presence of the expression of the human lysosomal-associated membrane protein, a widely expressed intracellular antigen for human cells (data not shown). The blood vessels that penetrated the Matrigel plugs were murine in origin based on MECA-32 expression (Figure 2e and f) , and did not express human endothelial antigens (Figure 2c and d) .
To counter the argument that the Matrigel plug system does not promote angiogenesis rapidly enough to detect the contribution of human leukemia cells, we used the woundhealing model, which is thought to promote more neoangiogenesis than the Matrigel plug system. Again, all of the vessels that grew in the healing wound in leukemic mice were of murine origin based on MECA-32 expression (Figure 2m and n) and lacked the expression of the human endothelial cell marker, von Willibrand factor.
Altogether, our studies demonstrate that although leukemia cells with t(4;11) produce angiogenic cytokines and receptors, they do not produce endothelial cells in Matrigel or the NOD/SCID xenograft model. This argues against the leukemia cell contributing to the walls of the blood vessels through a mechanism of vasculogenesis or vascular mimicry. This study suggests that t(4;11) infant leukemia cells are locked into a hemangioblastic state and are not able to differentiate to form normal blood cells or endothelium. In contrast to earlier studies using chronic myelogenous leukemia cells with BCR/ABL fusion, t(4;11) leukemia cells did not contribute to blood vessel walls in areas infiltrated with leukemia. This may be related to biological differences between chronic myelogenous leukemia, where during the chronic phase, malignant progenitor cells are not maturationally arrested and can produce mature progeny. Although they express genes that are similar to hemangioblasts, t(4;11) leukemia cells seem to be arrested at a primitive stage and are unable to produce mature progeny. This heterogeneity in the ability to produce mature progeny has been demonstrated using fluorescence in situ hybridization studies to study the lineage relationships of cells containing various clonotypic mutations that lead to leukemogenesis. In these studies, certain types of AML (those due to AML/ETO translocation in particular) have been shown to have the translocation in mature cells. This would suggest that if leukemia can produce endothelial cells, this ability is not universal but rather specific to certain sorts of leukemia. Furthermore, because leukemia arises from a stepwise process of sequential mutations, one must be careful not to equate the presence of a mutation such as AML/ETO in an endothelial cell as a proof that leukemia can behave as an angioblast.
These studies were undertaken to assess the rationale for using antiangiogenesis therapy to treat infant leukemia. Our studies suggest that t(4;11) leukemia cells recruit blood vessels but do not contribute to the walls of the blood vessels in leukemiainfiltrated areas. Overexpression of VEGF-A as well as a number of other angiogenic cytokines such as VE-cadherin would suggest that antiangiogenic therapy might still be a fruitful approach in treating infant leukemia. Further studies focused on the effect of inhibiting these pathways on the growth of t(4;11) cells are underway.
